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substance P, and nitric oxide) have also been shown to contribute to
UVB-induced erythema (Benrath et al, 1995), immunosuppression
(Gillardon et al, 1995), and production of cytokines like TNF-α in
mast cells (Ansel et al, 1993; Niizeki et al, 1997). Because GABA is an
inhibitory neurotransmitter, it might be possible that cis-UCA binds as
an antagonist to possible cutaneous GABA receptors. Such function
could disinhibit the secretion of cutaneous neuropeptides modulating
local immune reactions. Because no reports of GABA receptors in the
skin have been found, our next goal will be to study whether GABA
receptors exist in the skin.
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UV Immunosuppression and Skin Cancer
To the Editor:
We read with considerable interest the paper by Yamawaki et al
‘‘Genetic variation in low-dose UV-induced suppression of contact
hypersensitivity and in the skin photocarcinogenesis response,’’ pub-
lished in the Journal of Investigative Dermatology (109:716, 1997). The
data in Figs 4 and 5 of this paper compare tumor incidence and tumor
yield in C3H/HeN and C3H/HeJ mice treated with either UV alone
(Fig 4) or a single dose of UV followed by 12-O-tetradecanoyl-
phorbol-13-acetate promotion (Fig 5). These two mouse strains differ
in the Lps gene that is defective in C3H/HeJ mice and controls a
variety of B lymphocyte and macrophage responses. These mice
have also been reported to differ in susceptibility to the ‘‘local’’
immunosuppressive effects of UV radiation, proposed to be an import-
ant factor in UV carcinogenesis. We have some comments on this paper.
Statistical analysis It is stated (p. 719) that there are significant
differences in tumor incidence and yield between the two strains in
Fig 5, i.e., after treatment with UV and 12-O-tetradecanoyl-phorbol-
13-acetate, but not in Fig 4, i.e., after treatment with UV alone. By
visual inspection this would appear to be the case, but we were unable
to find any mention of any statistical test for significance. It is essential
to see the results of the application to this data, e.g., survival analysis
with censoring, which accounts for any tumor-free deaths during the
experiment, and appropriate statistical analysis, e.g., Kaplan–Meier
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logrank test, before it can be concluded that significant differences do
in fact exist.
Strain differences in UV immunosuppression There is not
universal agreement that C3H/HeN and C3H/HeJ strains do differ in
susceptibility to the immunosuppressive effects of UV. The UV dose–
responses for suppression of contact hypersensitivity in these two strains
are in fact identical if the ‘‘systemic’’ model is used (Noonan and De
Fabo, 1990) and would have predicted the findings in Fig 4.
‘‘Low-dose’’ versus ‘‘high-dose’’ immunosuppression It is simply
incorrect to say, as is stated in the Introduction (p. 716), that ‘‘A
relatively low dose of UV radiation is all that is required to produce
immunosuppression if the antigen is applied directly to the UV-exposed
skin site (local or low-dose immune suppression). On the other hand,
when a greater UV dose is administered, immunosuppression results
even if the antigen is applied to a non-UV exposed skin site (systemic
or high-dose immune suppression).’’
In fact, a direct comparison between UV-induced ‘‘local’’ and
‘‘systemic’’ immunosuppression of contact hypersensitivity showed that
the UV dose–responses for these effects are the same (Noonan and De
Fabo, 1990). The UV dose–responses differ, however, between mouse
strains (Noonan and De Fabo, 1990; Noonan and Hoffman, 1994) and
the kinetics of ‘‘local’’ and ‘‘systemic’’ suppression differ. A time lag of
2–3 d after UV before antigen application has long been known to be
necessary for the detection of systemic suppression (Noonan et al,
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1981; Molendijk et al, 1987), presumably to allow the generation of
systemic mediators of immunosuppression.
Further, it has also long been known that 50% ‘‘systemic’’ suppression
can be generated by UV doses as low as 420 J per m2 of 270 nm
(61.5 nm HBW) narrow band UV in the ‘‘UV-resistant’’ strain BALB/
C (De Fabo and Noonan, 1983). Finally, we would strongly suggest
that use of the terms ‘‘low-dose’’ and ‘‘high-dose’’ are qualitative and
therefore intrinsically unsatisfactory. As far as we can establish neither
term has been quantitatively defined.
Strain differences and hapten dose We disagree with the conclu-
sion (p. 720, para 2) that ‘‘strain differences are observed only when
excessive amounts of hapten are used for immunization.’’ The dose
of hapten appears to change the doses of UV required for UV
immunosuppression (Figs 1–3), as reported (Miyauchi and Horio,
1995) and cited in the current paper; however, unless UV dose–
responses for immunosuppression are established for each mouse strain
at each hapten dose, it cannot be stated that the strain differences in
susceptibility to UV-induced immunosuppression are observed ‘‘only’’
when excessive amounts of hapten are used for immunization.
Frances Noonan, Edward C. De Fabo
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Reply:
Drs. Noonan and DeFabo raise several relevant questions with respect
to our manuscript ‘‘Genetic variation in low-dose UV-induced
suppression of contact hypersensitivity and in the skin
photocarcinogenesis response’’ that was recently published in the Journal
of Investigative Dermatology (109:716, 1997).
Statistical analysis Statistical analysis was performed on the
carcinogenesis experiments employing Chi square analysis and was not
statistically significant for the two strains when they were subjected to
the chronic UV irradiation protocol, but were highly significant
(p , 0.01) when panels were given the single dose of UV radiation
followed by repeated applications to 12-O-tetradecanoyl-phorbol-
13-acetate.
‘‘Low-dose’’ versus ‘‘high-dose’’ immunosuppression Although
we agree that ‘‘low dose’’ and ‘‘high dose’’ may not be the ideal
terms for the two different protocols used to produce UV-induced
immunosuppression, they are the generally accepted terms. It would
only add further confusion to the literature to change the terms at this
point. Although we have not performed the experiments ourselves,
we have no reason to disagree with the statement that systemic
immunosuppression of the contact hypersensitivity response can be
produced at considerably lower doses than are generally employed. It
is important to note that Drs. Noonan and De Fabo have reported
that lower doses of UV radiation can produce ‘‘high-dose’’
immunosuppression, not every investigator has found this to be the
case (Toews et al, 1980; Elmets et al, 1983; Jun et al, 1988). Moreover,
whether those lower doses can be used to suppress the response to
other immunogens – e.g., to Herpes simplex virus – remains to be
determined (Ross et al, 1986). It is important to emphasize that there
are clear-cut differences in the mechanisms by which these two
UV irradiation protocols produce immunosuppression (Elmets and
Bergstresser, 1982; Cruz and Bergstresser, 1992). First, ‘‘low dose’’ UV-
induced suppression of contact hypersensitivity is mediated at least in
part by an alteration in the antigen-presenting function of epidermal
Langerhans cells and other antigen-presenting cells in the skin (Toews
et al, 1980). In contrast, Langerhans cell antigen-presenting function
in the skin to which hapten is applied in the ‘‘high-dose’’ UV irradiation
regimen is normal (Noonan et al, 1988). Second, the soluble mediators
associated with the two regimens differ. TNF-α has been shown to
suppress induction of contact hypersensitivity in the ‘‘low-dose’’
model (Streilein, 1995), whereas IL-10 is a major mediator of the
immunosuppression in the ‘‘high-dose’’ model (Rivas and Ullrich,
1992, 1994; Ullrich, 1995). Third, there may be differences in the
chromophores that mediate the immunosuppressive effects in the two
regimens (Applegate et al, 1989; Norval et al, 1989; Kripke et al, 1992).
Finally, Dr. Noonan’s own data suggest that the two regimens are
mechanistically different, because the strains of mice that exhibit
immunosuppression following treatment with the ‘‘high-dose’’ regimen
(Noonan and Hoffman, 1994a, b) are quite different from those with
the ‘‘low-dose’’ regimen (Streilein and Bergstresser, 1988; Yoshikawa
and Streilein, 1990).
Strain differences in UV immunosuppression As referred to
above, the fact that Dr. Noonan did not find differences in the
immunosuppressive whereas we and others have most likely relates to
differences in the ‘‘low-dose’’ and ‘‘high-dose’’ UV-irradiation regimens.
We disagree with Drs. Noonan’s and DeFabo’s conclusion that our
findings would have been predicted from the ‘‘systemic’’ model,
because the ‘‘systemic’’ model was not used in this situation. The
presumed tumor antigens to which the immune response is deficient
were present only at the irradiated skin site.
Strain differences and hapten dose What we meant to say was
that ‘‘at the UV-dose employed strain differences are observed only
when excessive amount of hapten are used for immunization.’’
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